• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2013年中国癌症的发病率与死亡率:基于城市化水平的分析

Cancer incidence and mortality in China in 2013: an analysis based on urbanization level.

作者信息

Chen Wanqing, Zheng Rongshou, Zhang Siwei, Zeng Hongmei, Zuo Tingting, Xia Changfa, Yang Zhixun, He Jie

机构信息

National Central Cancer Registry, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

出版信息

Chin J Cancer Res. 2017 Feb;29(1):1-10. doi: 10.21147/j.issn.1000-9604.2017.01.01.

DOI:10.21147/j.issn.1000-9604.2017.01.01
PMID:28373748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5348470/
Abstract

OBJECTIVE

To explore the cancer patterns in areas with different urbanization rates (URR) in China with data from 255 population-based cancer registries in 2013, collected by the National Central Cancer Registry (NCCR).

METHODS

There were 347 cancer registries submitted cancer incidence and deaths occurred in 2013 to NCCR. All those data were checked and evaluated based on the NCCR criteria of data quality, and qualified data from 255 registries were used for this analysis. According to the proportion of non-agricultural population, we divided cities/counties into 3 levels: high level, with URR equal to 70% and higher; median level, with URR between 30% and 70%; and low level, with URR equal to 30% and less. Cancer incidences and mortalities were calculated, stratified by gender and age groups in different areas. The national population of Fifth Census in 2000 and Segi's population were applied for age-standardized rates.

RESULTS

Qualified 255 cancer registries covered 226,494,490 populations. The percentage of cases morphologically verified (MV%) and death certificate-only cases (DCO%) were 68.04% and 1.74%, respectively, and the mortality to incidence rate ratio (M/I) was 0.62. A total of 644,487 new cancer cases and 399,275 cancer deaths from the 255 cancer registries were submitted to NCCR in 2013. The incidence rate was 284.55/100,000 (314.06/100,000 in males, 254.19/100,000 in females), and the age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 190.10/100,000 and 186.24/100,000 with the cumulative incidence rate (0-74 age years old) of 21.60%. The cancer mortality was 176.28/100,000 (219.03/100,000 in males, 132.30/100,000 in females), and the age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 110.91/100,000 and 109.92/100,000, and the cumulative mortality rate (0-74 age years old) was 12.43%. Low urbanization areas were high in crude cancer incidence and mortality rates, middle urbanization areas came next to it followed by high urbanization areas. After adjusted by age, there was a U-shaped association between age-standardized incidence (ASIRC and ASIRW) and the urbanized ratio with the middle urbanization areas having the lowest ASIRC and ASIRW. Unlike with the age-standardized incidence, the sort order of age-standardized mortality (ASMRC and ASMRW) among three urbanization areas was reversed completely from the crude mortality. Lung cancer was the most common cancer in all areas of 255 cancer registries, followed by stomach cancer, liver cancer, colorectal cancer and esophageal cancer with new cases of 130,700, 76,200, 63,800, 60,900 and 50,200 respectively. Lung cancer was also the leading cause of cancer death in all areas of 255 cancer registries for both males and females with the number of deaths of 72,200 and 34,100, respectively. Other cancer types with high mortality in males were liver cancer, stomach cancer, esophageal cancer and colorectal cancer. In females, stomach cancer was the second cause of cancer death, followed by liver cancer, colorectal cancer and breast cancer.

CONCLUSIONS

Along with the development of socioeconomics associated with urbanization, as well as the aging population, the incidence and mortality keep increasing in China. Cancer burden and patterns are different in each urbanization level. Cancer control strategies should be implemented referring to local urbanization status.

摘要

目的

利用国家癌症中心(NCCR)收集的2013年来自255个基于人群的癌症登记处的数据,探讨中国不同城市化率地区的癌症模式。

方法

共有347个癌症登记处向NCCR提交了2013年发生的癌症发病率和死亡数据。所有这些数据均根据NCCR的数据质量标准进行检查和评估,并使用来自255个登记处的合格数据进行本分析。根据非农业人口比例,将市/县分为3个级别:高城市化率地区,城市化率等于或高于70%;中等城市化率地区,城市化率在30%至70%之间;低城市化率地区,城市化率等于或低于30%。计算不同地区按性别和年龄组分层的癌症发病率和死亡率。采用2000年第五次全国人口普查的全国人口数据和Segi人口数据计算年龄标准化率。

结果

255个合格癌症登记处覆盖了226494490人。形态学确诊病例百分比(MV%)和仅死亡证明病例百分比(DCO%)分别为68.04%和1.74%,死亡率与发病率之比(M/I)为0.62。2013年,255个癌症登记处共向NCCR提交了644487例新发癌症病例和399275例癌症死亡病例。发病率为284.55/10万(男性为314.06/10万,女性为254.19/10万),按中国标准人口计算的年龄标准化发病率(ASIRC)和按世界标准人口计算的年龄标准化发病率(ASIRW)分别为190.10/10万和186.24/10万,累积发病率(0至74岁)为21.60%。癌症死亡率为176.28/10万(男性为219.03/10万,女性为132.30/10万),按中国标准人口计算的年龄标准化死亡率(ASMRC)和按世界标准人口计算的年龄标准化死亡率(ASMRW)分别为110.91/10万和109.92/10万,累积死亡率(0至74岁)为12.43%。低城市化地区的癌症粗发病率和死亡率较高,中等城市化地区次之,高城市化地区最低。按年龄调整后,年龄标准化发病率(ASIRC和ASIRW)与城市化率呈U形关联,中等城市化地区的ASIRC和ASIRW最低。与年龄标准化发病率不同,三个城市化地区年龄标准化死亡率(ASMRC和ASMRW)的排序与粗死亡率完全相反。肺癌是255个癌症登记处所有地区最常见的癌症,其次是胃癌、肝癌、结直肠癌和食管癌,新发病例分别为130700例、76200例、63800例、60900例和50200例。肺癌也是255个癌症登记处所有地区男性和女性癌症死亡的主要原因,死亡人数分别为72200例和34100例。男性其他高死亡率癌症类型为肝癌、胃癌、食管癌和结直肠癌。在女性中,胃癌是癌症死亡的第二大原因,其次是肝癌、结直肠癌和乳腺癌。

结论

随着与城市化相关的社会经济发展以及人口老龄化,中国的癌症发病率和死亡率持续上升。不同城市化水平的癌症负担和模式各不相同。应参照当地城市化状况实施癌症控制策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1dd/5348470/24873fd78442/cjcr-29-1-1-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1dd/5348470/24873fd78442/cjcr-29-1-1-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1dd/5348470/24873fd78442/cjcr-29-1-1-1.jpg

相似文献

1
Cancer incidence and mortality in China in 2013: an analysis based on urbanization level.2013年中国癌症的发病率与死亡率:基于城市化水平的分析
Chin J Cancer Res. 2017 Feb;29(1):1-10. doi: 10.21147/j.issn.1000-9604.2017.01.01.
2
Cancer incidence and mortality in Shandong province, 2012.2012年山东省癌症发病率与死亡率
Chin J Cancer Res. 2016 Jun;28(3):263-74. doi: 10.21147/j.issn.1000-9604.2016.03.01.
3
Cancer incidence and mortality in Henan province, 2012.2012年河南省癌症发病率与死亡率
Chin J Cancer Res. 2016 Jun;28(3):275-85. doi: 10.21147/j.issn.1000-9604.2016.03.02.
4
Estimated cancer incidence and mortality in Hebei province, 2012.2012年河北省癌症发病率及死亡率估计
Chin J Cancer Res. 2016 Jun;28(3):286-300. doi: 10.21147/j.issn.1000-9604.2016.03.03.
5
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.暴力死亡监测——2022年全国暴力死亡报告系统,50个州、哥伦比亚特区和波多黎各
MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1.
6
Surveillance for Violent Deaths - National Violent Death Reporting System, 48 States, the District of Columbia, and Puerto Rico, 2020.暴力死亡监测 - 全国暴力死亡报告系统,2020 年,48 个州、哥伦比亚特区和波多黎各。
MMWR Surveill Summ. 2023 May 26;72(5):1-38. doi: 10.15585/mmwr.ss7205a1.
7
National cancer incidence and mortality in China, 2012.2012年中国国家癌症发病率与死亡率
Chin J Cancer Res. 2016 Feb;28(1):1-11. doi: 10.3978/j.issn.1000-9604.2016.02.08.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
10
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.

引用本文的文献

1
Age-related and postmenopausal breast cancer progression and treatment management: The significance of pro-inflammatory cytokines and CXC chemokines.年龄相关性及绝经后乳腺癌的进展与治疗管理:促炎细胞因子和CXC趋化因子的意义
Genes Dis. 2025 Mar 19;12(5):101606. doi: 10.1016/j.gendis.2025.101606. eCollection 2025 Sep.
2
Ovarian metastasis from lobular breast carcinoma: A case report with review of literature.小叶性乳腺癌卵巢转移:一例病例报告并文献复习
Radiol Case Rep. 2025 Apr 5;20(6):3099-3105. doi: 10.1016/j.radcr.2025.03.043. eCollection 2025 Jun.
3
Astragaloside IV accelerates hematopoietic reconstruction by improving the AMPK/PGC1α-mediated mitochondrial function in hematopoietic stem cells.

本文引用的文献

1
National cancer incidence and mortality in China, 2012.2012年中国国家癌症发病率与死亡率
Chin J Cancer Res. 2016 Feb;28(1):1-11. doi: 10.3978/j.issn.1000-9604.2016.02.08.
2
The association between lung cancer incidence and ambient air pollution in China: A spatiotemporal analysis.中国肺癌发病率与环境空气污染之间的关联:一项时空分析。
Environ Res. 2016 Jan;144(Pt A):60-65. doi: 10.1016/j.envres.2015.11.004. Epub 2015 Nov 9.
3
Annual report on status of cancer in China, 2011.《2011年中国癌症现状年度报告》
黄芪甲苷IV通过改善造血干细胞中AMPK/PGC1α介导的线粒体功能来加速造血重建。
Chin Med. 2025 Apr 1;20(1):44. doi: 10.1186/s13020-025-01092-3.
4
MFAP5 inhibits the malignant progression of endometrial cancer cells .MFAP5抑制子宫内膜癌细胞的恶性进展。
Open Life Sci. 2024 Dec 31;19(1):20220990. doi: 10.1515/biol-2022-0990. eCollection 2024.
5
Discovery and validation of Hsa-microRNA-3665 promoter methylation as a potential biomarker for the prognosis of esophageal squaous cell carcinoma.人源微小RNA-3665启动子甲基化作为食管鳞状细胞癌预后潜在生物标志物的发现与验证
Int J Clin Oncol. 2025 Feb;30(2):309-319. doi: 10.1007/s10147-024-02656-3. Epub 2024 Dec 4.
6
Descriptive epidemiology of prostate cancer in India, 2012-2019: Insights from the National Cancer Registry Programme.2012 - 2019年印度前列腺癌的描述性流行病学:来自国家癌症登记计划的见解
Indian J Urol. 2024 Jul-Sep;40(3):167-173. doi: 10.4103/iju.iju_27_24. Epub 2024 Jul 1.
7
Latest insights into the global epidemiological features, screening, early diagnosis and prognosis prediction of esophageal squamous cell carcinoma.食管鳞状细胞癌全球流行病学特征、筛查、早期诊断及预后预测的最新研究进展。
World J Gastroenterol. 2024 May 28;30(20):2638-2656. doi: 10.3748/wjg.v30.i20.2638.
8
5-Fluorouracil resistant CRC cells derived exosomes promote cancer-associated fibroblasts secreting more CXCL12.源自5-氟尿嘧啶耐药性结直肠癌细胞的外泌体促进癌症相关成纤维细胞分泌更多的CXCL12。
J Cancer. 2024 Apr 29;15(11):3441-3451. doi: 10.7150/jca.95248. eCollection 2024.
9
Efficacy and safety of chemotherapy as monotherapy in patients with recurrent intermediate/high-risk factors following radical hysterectomy for stage IB-IIA cervical cancer: a single-center retrospective analysis.根治性子宫切除术治疗 IB 期至 IIA 期宫颈癌后,复发中/高危因素患者采用化疗单药治疗的疗效和安全性:单中心回顾性分析。
BMC Womens Health. 2024 May 18;24(1):297. doi: 10.1186/s12905-024-03135-7.
10
Nutraceutical Properties of Syringic Acid in Civilization Diseases-Review.丁香酸在文明病中的营养特性-综述。
Nutrients. 2023 Dec 19;16(1):10. doi: 10.3390/nu16010010.
Chin J Cancer Res. 2015 Feb;27(1):2-12. doi: 10.3978/j.issn.1000-9604.2015.01.06.
4
Cancer survival in China, 2003-2005: a population-based study.2003 - 2005年中国癌症生存率:一项基于人群的研究。
Int J Cancer. 2015 Apr 15;136(8):1921-30. doi: 10.1002/ijc.29227. Epub 2014 Oct 3.
5
Household air pollution and lung cancer in China: a review of studies in Xuanwei.中国的家庭空气污染与肺癌:对宣威研究的综述
Chin J Cancer. 2014 Oct;33(10):471-5. doi: 10.5732/cjc.014.10132. Epub 2014 Sep 16.
6
Annual report on status of cancer in China, 2010.《中国癌症报告 2010》年度报告
Chin J Cancer Res. 2014 Feb;26(1):48-58. doi: 10.3978/j.issn.1000-9604.2014.01.08.
7
Epidemiology of lung cancer.肺癌流行病学
Semin Intervent Radiol. 2013 Jun;30(2):93-8. doi: 10.1055/s-0033-1342949.
8
Cancer incidence and mortality in china, 2006.中国 2006 年癌症发病与死亡。
Chin J Cancer Res. 2011 Mar;23(1):3-9. doi: 10.1007/s11670-011-0003-9.
9
Report of incidence and mortality in China cancer registries, 2009.中国癌症登记地区 2009 年肿瘤登记发病与死亡报告
Chin J Cancer Res. 2013 Feb;25(1):10-21. doi: 10.3978/j.issn.1000-9604.2012.12.04.
10
Cancer incidence and mortality in china, 2007.中国 2007 年癌症发病与死亡。
Chin J Cancer Res. 2012 Mar;24(1):1-8. doi: 10.1007/s11670-012-0001-6.